Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($1.33), $0.19 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $840 thousand versus the consensus estimate of $1.05 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.